

Ildiko Lingvay

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/960210/publications.pdf>

Version: 2024-02-01

122
papers

13,744
citations

76326

40
h-index

26613

107
g-index

127
all docs

127
docs citations

127
times ranked

8904
citing authors

#	ARTICLE	IF	CITATIONS
1	Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2016, 375, 1834-1844.	27.0	3,898
2	Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 2021, 384, 989-1002.	27.0	1,374
3	Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine, 2019, 381, 841-851.	27.0	1,002
4	Cardiac Steatosis in Diabetes Mellitus. Circulation, 2007, 116, 1170-1175.	1.6	535
5	Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, open-label, phase 3b trial. Lancet Diabetes and Endocrinology, 2018, 6, 275-286.	11.4	443
6	Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet, 2021, 397, 971-984.	13.7	429
7	Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity. JAMA - Journal of the American Medical Association, 2021, 325, 1414.	7.4	413
8	Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity. JAMA - Journal of the American Medical Association, 2021, 325, 1403.	7.4	387
9	Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial. Diabetes Care, 2018, 41, 258-266.	8.6	350
10	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet, 2019, 394, 39-50.	13.7	315
11	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503.	27.0	228
12	Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled Trial. Journal of Clinical Endocrinology and Metabolism, 2018, 103, 2291-2301.	3.6	225
13	Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care, 2019, 42, 2272-2281.	8.6	225
14	Obesity management as a primary treatment goal for type 2 diabetes: time to reframe the conversation. Lancet, 2022, 399, 394-405.	13.7	215
15	Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes. JAMA - Journal of the American Medical Association, 2016, 315, 898.	7.4	181
16	Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes, Obesity and Metabolism, 2018, 20, 889-897.	4.4	173
17	Noninvasive Quantification of Pancreatic Fat in Humans. Journal of Clinical Endocrinology and Metabolism, 2009, 94, 4070-4076.	3.6	167
18	Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022, 24, 1553-1564.	4.4	151

#	ARTICLE	IF	CITATIONS
19	Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 834-844.	11.4	149
20	Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. <i>Obesity</i> , 2020, 28, 1050-1061.	3.0	148
21	Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial. <i>Diabetes Care</i> , 2019, 42, 2262-2271.	8.6	146
22	Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity (SELECT) rationale and design. <i>American Heart Journal</i> , 2020, 229, 61-69.	2.7	137
23	Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. <i>Diabetes and Metabolism</i> , 2019, 45, 409-418.	2.9	114
24	The SGLT2 inhibitor canagliflozin in heart failure: the CHIEF-HF remote, patient-centered randomized trial. <i>Nature Medicine</i> , 2022, 28, 809-813.	30.7	107
25	Pancreatic Steatosis and Its Relationship to β -Cell Dysfunction in Humans. <i>Diabetes Care</i> , 2012, 35, 2377-2383.	8.6	102
26	Semaglutide (SUSTAIN and PIONEER) reduces cardiovascular events in type 2 diabetes across varying cardiovascular risk. <i>Diabetes, Obesity and Metabolism</i> , 2020, 22, 442-451.	4.4	102
27	Rapid Improvement in Diabetes After Gastric Bypass Surgery. <i>Diabetes Care</i> , 2013, 36, 2741-2747.	8.6	98
28	β -Cell Function Preservation After 3.5 Years of Intensive Diabetes Therapy. <i>Diabetes Care</i> , 2012, 35, 1406-1412.	8.6	87
29	Insulin-Based Versus Triple Oral Therapy for Newly Diagnosed Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 1789-1795.	8.6	85
30	Hyposialylated IgG activates endothelial IgG receptor Fc γ RIIB to promote obesity-induced insulin resistance. <i>Journal of Clinical Investigation</i> , 2017, 128, 309-322.	8.2	82
31	Association of Statin Therapy Initiation With Diabetes Progression. <i>JAMA Internal Medicine</i> , 2021, 181, 1562.	5.1	80
32	Efficacy and safety of once-weekly semaglutide 2.4 mg versus 1.0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 563-574.	11.4	79
33	Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial. <i>Cardiovascular Diabetology</i> , 2019, 18, 73.	6.8	69
34	Effect of Pioglitazone Therapy on Myocardial and Hepatic Steatosis in Insulin-Treated Patients with Type 2 Diabetes. <i>Journal of Investigative Medicine</i> , 2007, 55, 230-236.	1.6	63
35	Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial. <i>Diabetes Care</i> , 2021, 44, 1586-1594.	8.6	56
36	A 26-Week Randomized Controlled Trial of Semaglutide Once Daily Versus Liraglutide and Placebo in Patients With Type 2 Diabetes Suboptimally Controlled on Diet and Exercise With or Without Metformin. <i>Diabetes Care</i> , 2018, 41, 1926-1937.	8.6	49

#	ARTICLE	IF	CITATIONS
37	Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. <i>Postgraduate Medicine</i> , 2022, 134, 14-19.	2.0	46
38	Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. <i>Expert Review of Cardiovascular Therapy</i> , 2011, 9, 321-328.	1.5	43
39	Effect of insulin+metformin combination on hepatic steatosis in patients with type 2 diabetes. <i>Journal of Diabetes and Its Complications</i> , 2007, 21, 137-142.	2.3	42
40	Outpatient metformin use is associated with reduced severity of COVID-19 disease in adults with overweight or obesity. <i>Journal of Medical Virology</i> , 2021, 93, 4273-4279.	5.0	41
41	A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100. <i>Diabetes Care</i> , 2021, 44, 1595-1603.	8.6	41
42	Type 1 Diabetes Treatment beyond Insulin: Role of GLP-1 Analogs. <i>Journal of Investigative Medicine</i> , 2013, 61, 40-44.	1.6	40
43	Mechanisms of Action of Liraglutide in Patients With Type 2 Diabetes Treated With High-Dose Insulin. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 1798-1806.	3.6	40
44	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol+Rationale, Design, and Baseline Data. <i>Diabetes Care</i> , 2019, 42, 1454-1463.	8.6	39
45	Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome. <i>Diabetes/Metabolism Research and Reviews</i> , 2015, 31, 734-744.	4.0	37
46	Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial. <i>Diabetologia</i> , 2020, 63, 473-485.	6.3	37
47	Incorporating SGLT2i and GLP-1RA for Cardiovascular and Kidney Disease Risk Reduction: Call for Action to the Cardiology Community. <i>Circulation</i> , 2021, 144, 74-84.	1.6	34
48	Gastrointestinal tolerability of once-weekly semaglutide 2.4mg in adults with overweight or obesity, and the relationship between gastrointestinal adverse events and weight loss. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 94-105.	4.4	34
49	Effect of Adding Liraglutide vs Placebo to a High-Dose Insulin Regimen in Patients With Type 2 Diabetes. <i>JAMA Internal Medicine</i> , 2016, 176, 939.	5.1	33
50	Association of Galectin-3 With Diabetes Mellitus in the Dallas Heart Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2019, 104, 4449-4458.	3.6	33
51	Random Blood Glucose: A Robust Risk Factor For Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 1503-1510.	3.6	32
52	Effect of medication adherence on clinical outcomes in type 2 diabetes: analysis of the SIMPLE study. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000761.	2.8	32
53	Insulin as Initial Therapy in Type 2 Diabetes. <i>Journal of Investigative Medicine</i> , 2007, 55, 62-68.	1.6	31
54	Switching Between Glucagon-Like Peptide-1 Receptor Agonists: Rationale and Practical Guidance. <i>Clinical Diabetes</i> , 2020, 38, 390-402.	2.2	31

#	ARTICLE	IF	CITATIONS
55	Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001706.	2.8	31
56	Pharmacotherapies for Post-Bariatric Weight Regain: Real-World Comparative Outcomes. <i>Obesity</i> , 2021, 29, 829-836.	3.0	30
57	Use of Lipid-, Blood Pressure-, and Glucose-Lowering Pharmacotherapy in Patients With Type 2 Diabetes and Atherosclerotic Cardiovascular Disease. <i>JAMA Network Open</i> , 2022, 5, e2148030.	5.9	30
58	Quantification of renal steatosis in type II diabetes mellitus using dixon-based MRI. <i>Journal of Magnetic Resonance Imaging</i> , 2016, 44, 1312-1319.	3.4	27
59	Effects of semaglutide on risk of cardiovascular events across a continuum of cardiovascular risk: combined post hoc analysis of the SUSTAIN and PIONEER trials. <i>Cardiovascular Diabetology</i> , 2020, 19, 156.	6.8	25
60	Insights into the early use of oral semaglutide in routine clinical practice: The <sc>IGNITE</sc> study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2177-2182.	4.4	25
61	Brief report: Depression and history of suicide attempts in adults with new-onset Type 2 Diabetes. <i>Psychoneuroendocrinology</i> , 2013, 38, 2810-2814.	2.7	23
62	When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy. <i>Diabetes/Metabolism Research and Reviews</i> , 2018, 34, e2981.	4.0	23
63	Novel Trial Design: CHIEF-HF. <i>Circulation: Heart Failure</i> , 2021, 14, e007767.	3.9	23
64	Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program. <i>Diabetes Care</i> , 2022, 45, 2396-2405.	8.6	19
65	Outcomes in GLP-1 RA-Experienced Patients Switching to Once-Weekly Semaglutide in a Real-World Setting: The Retrospective, Observational EXPERT Study. <i>Diabetes Therapy</i> , 2021, 12, 879-896.	2.5	18
66	The fatty hearts of patients with diabetes. <i>Nature Reviews Cardiology</i> , 2009, 6, 268-269.	13.7	17
67	The Infamous, Famous Sulfonylureas and Cardiovascular Safety: Much Ado About Nothing?. <i>Current Diabetes Reports</i> , 2017, 17, 124.	4.2	17
68	Roux-Y gastric bypass compared with equivalent diet restriction: Mechanistic insights into diabetes remission. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 1710-1721.	4.4	17
69	Heart failure with insulin degludec versus glargine U100 in patients with type 2 diabetes at high risk of cardiovascular disease: DEVOTE 14. <i>Cardiovascular Diabetology</i> , 2019, 18, 156.	6.8	17
70	Efficacy and Safety of Semaglutide Once-Weekly vs. Placebo as Add-on to Basal Insulin Alone or in Combination with Metformin in Subjects with Type 2 Diabetes (SUSTAIN 5). <i>Canadian Journal of Diabetes</i> , 2016, 40, S41-S42.	0.8	14
71	Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the <sc>DUAL V</sc> randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2018, 20, 200-205.	4.4	14
72	An indirect treatment comparison of the efficacy of semaglutide 1.0 mg versus dulaglutide 3.0 and 4.5 mg. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 2513-2520.	4.4	14

#	ARTICLE	IF	CITATIONS
73	Intensive Therapy in Newly Diagnosed Type 2 Diabetes. Journal of Investigative Medicine, 2014, 62, 676-686.	1.6	13
74	Use of GLP-1 RAs in Cardiovascular Disease Prevention. Circulation, 2018, 137, 2200-2202.	1.6	13
75	Triple fixed-dose combination empagliflozin, linagliptin, and metformin for patients with type 2 diabetes. Postgraduate Medicine, 2020, 132, 337-345.	2.0	13
76	Performance of a Random Glucose Case-Finding Strategy to Detect Undiagnosed Diabetes. American Journal of Preventive Medicine, 2017, 52, 710-716.	3.0	12
77	Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. Journal of Clinical Endocrinology and Metabolism, 2020, 105, e4593-e4604.	3.6	12
78	Long-term Outcomes of Thyroid Nodule AFIRMA GEC Testing and Literature Review: An Institutional Experience. Otolaryngology - Head and Neck Surgery, 2020, 162, 634-640.	1.9	12
79	Effect of Insulin versus Triple Oral Therapy on the Progression of Hepatic Steatosis in Type 2 Diabetes. Journal of Investigative Medicine, 2012, 60, 1059-1063.	1.6	11
80	The metabolic cost of lowering blood pressure with hydrochlorothiazide. Diabetology and Metabolic Syndrome, 2013, 5, 35.	2.7	11
81	Sodium Glucose Cotransporter 2 and Dipeptidyl Peptidase-4 Inhibition: Promise of a Dynamic Duo. Endocrine Practice, 2017, 23, 831-840.	2.1	11
82	Risk of severe hypoglycaemia and its impact in type 2 diabetes in DEVOTE. Diabetes, Obesity and Metabolism, 2020, 22, 2241-2247.	4.4	11
83	An Indirect Treatment Comparison of Semaglutide 2.0 mg vs Dulaglutide 3.0 mg and 4.5 mg Using Multilevel Network Meta-regression. Journal of Clinical Endocrinology and Metabolism, 2022, 107, 1461-1469.	3.6	9
84	Development of a hypoglycaemia risk score to identify high-risk individuals with advanced type 2 diabetes in DEVOTE. Diabetes, Obesity and Metabolism, 2020, 22, 2248-2256.	4.4	8
85	Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study. Endocrinology, Diabetes and Metabolism, 2021, 4, e00170.	2.4	8
86	Efficacy and safety of ertugliflozin in patients with type 2 diabetes mellitus and established cardiovascular disease using insulin: A VERTIS CV substudy. Diabetes, Obesity and Metabolism, 2021, 23, 1640-1651.	4.4	8
87	Impact of bariatric surgery on cerebral vascular reactivity and cognitive function: a non-randomized pilot study. Pilot and Feasibility Studies, 2020, 6, 21.	1.2	7
88	Once-weekly Subcutaneous Semaglutide 2.4 mg Reduces Body Weight in Adults with Overweight or Obesity Regardless of Baseline Characteristics (STEP 1). Journal of the Endocrine Society, 2021, 5, A24-A24.	0.2	7
89	Doc, I Just Ate: Interpreting Random Blood Glucose Values in Patients with Unknown Glycemic Status. Journal of General Internal Medicine, 2018, 33, 142-144.	2.6	6
90	Impact of patient characteristics on efficacy and safety of once-weekly semaglutide versus dulaglutide: SUSTAIN 7 post hoc analyses. BMJ Open, 2020, 10, e037883.	1.9	6

#	ARTICLE	IF	CITATIONS
91	Multilevel Variation in Diabetes Screening Within an Integrated Health System. <i>Diabetes Care</i> , 2020, 43, 1016-1024.	8.6	6
92	The effect of baseline characteristics on clinical efficacy of liraglutide in patients treated with high-dose insulin. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1454-1457.	4.4	5
93	Metabolic response 4 years after gastric bypass in a complete cohort with type 2 diabetes mellitus. <i>Diabetes Research and Clinical Practice</i> , 2018, 137, 224-230.	2.8	5
94	A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal-bolus insulin or a glucagon-like peptide-1 receptor agonist plus basal insulin: The SIMPLE study. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 2133-2141.	4.4	5
95	First-Line Use of Vemurafenib to Enable Thyroidectomy and Radioactive Iodine Ablation for BRAF-Positive Metastatic Papillary Thyroid Carcinoma. <i>Journal of Investigative Medicine High Impact Case Reports</i> , 2015, 3, 232470961560372.	0.6	4
96	Sweet's Syndrome and Subacute Thyroiditis: An Unrecognized Association?. <i>Thyroid</i> , 2010, 20, 1425-1426.	4.5	3
97	Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. <i>Diabetes, Obesity and Metabolism</i> , 2017, 19, 1562-1569.	4.4	3
98	Efficacy and Safety of Insulin Glargine 300 U/mL Versus Insulin Glargine 100 U/mL in High-Risk and Low-Risk Patients with Type 2 Diabetes Stratified Using Common Clinical Performance Measures. <i>Diabetes Technology and Therapeutics</i> , 2017, 19, 315-322.	4.4	3
99	Trends in the prevalence of cardiometabolic disease and cardiovascular events by body mass index category in adults from 1999 to 2016. <i>Postgraduate Medical Journal</i> , 2020, 96, 655-659.	1.8	3
100	Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs). <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001830.	2.8	3
101	Is insulin treatment a first-line defense against Type 2 diabetes?. <i>Expert Review of Cardiovascular Therapy</i> , 2010, 8, 483-485.	1.5	2
102	Impact of BMI on HbA1C Reduction in Response to IDegLira in Subjects with Type 2 Diabetes (T2D) Uncontrolled on SU, GLP-1RA or Insulin Glargine: Analyses from Completed Phase 3b Trials. <i>Canadian Journal of Diabetes</i> , 2017, 41, S58.	0.8	2
103	Clinically-Relevant Weight Loss is Achieved Independently of Early Weight Loss Response to Once-Weekly Subcutaneous Semaglutide 2.4 MG (STEP 4). <i>Journal of the Endocrine Society</i> , 2021, 5, A7-A7.	0.2	2
104	Insulin Sensitivity After Living Donor Nephrectomy. <i>Transplantation Proceedings</i> , 2021, 53, 1858-1864.	0.6	2
105	Response to Comment on: Harrison et al. ² Diabetes Care 2012;35:1406-1412. <i>Diabetes Care</i> , 2013, 36, e17-e17.	8.6	1
106	Weight Loss Maintenance With Once-Weekly Semaglutide 2.4 MG in Adults With Overweight or Obesity Reaching Maintenance Dose (STEP 4). <i>Journal of the Endocrine Society</i> , 2021, 5, A63-A64.	0.2	1
107	Efficacy and Safety of Semaglutide 2.4 MG Once-Weekly in Adults With Overweight or Obesity and Type 2 Diabetes (STEP 2). <i>Journal of the Endocrine Society</i> , 2021, 5, A10-A11.	0.2	1
108	Comparative Evaluation of Two Venous Sampling Techniques for the Assessment of Pancreatic Insulin and Zinc Release upon Glucose Challenge. <i>Journal of Diabetes Research</i> , 2015, 2015, 1-7.	2.3	0

#	ARTICLE	IF	CITATIONS
109	Patients with Type 2 Diabetes Treated with Insulin Degludec/Liraglutide Have a Greater Chance of Reaching Glycemic Targets Without Hypoglycemia and Weight Gain Than with Insulin Glargine. Canadian Journal of Diabetes, 2018, 42, S48.	0.8	0
110	Visual Vignette. Endocrine Practice, 2019, 25, 771.	2.1	0
111	Cover Image, Volume 22, Issue 3. Diabetes, Obesity and Metabolism, 2020, 22, .	4.4	0
112	Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease Using Insulin. Journal of the Endocrine Society, 2021, 5, A331-A332.	0.2	0
113	Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide 2.4 MG in Adults With Overweight or Obesity (STEP 1). Journal of the Endocrine Society, 2021, 5, A10-A10.	0.2	0
114	Back Cover Image, Volume 93, Number 7, July 2021. Journal of Medical Virology, 2021, 93, ii.	5.0	0
115	Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy and Body Weight in Adults With Overweight or Obesityâ€”Reply. JAMA - Journal of the American Medical Association, 2021, 326, 1214.	7.4	0
116	Pancreatic triglyceride levels: implications for type 2 diabetes development in ethnic minorities. FASEB Journal, 2012, 26, 686.20.	0.5	0
117	The impact of bariatric surgery on cerebral vascular reactivity. FASEB Journal, 2018, 32, 711.1.	0.5	0
118	Cardiovascular outcomes, safety, and tolerability with oral semaglutide: insights for managed care. American Journal of Managed Care, 2020, 26, S344-S355.	1.1	0
119	Strengthening a Study of Diabetes Progression After Statin Useâ€”Reply. JAMA Internal Medicine, 2022, 182, 460.	5.1	0
120	Obesity definition for personalised treatment of type 2 diabetes Â Authorsâ€™™ reply. Lancet, The, 2022, 399, 2189-2190.	13.7	0
121	Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs. 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0
122	Once-Weekly Semaglutide 1 mg vs Empagliflozin 25 mg as Add-On to Metformin Monotherapy in Patients with Type 2 Diabetes: a Meta-Regression Analysis of Individual Patient Data. Diabetologie Und Stoffwechsel, 2022, , .	0.0	0